Liposome‐Based Potential Vaccines Platforms that Are Noncytotoxic

Synthetic vaccines represent a promising avenue in cancer immunotherapy by promoting targeted immune responses. Liposomal technologies have further advanced synthetic vaccinology by enabling the efficient delivery of tumor-associated carbohydrate antigens. Despite this progress, the toxicity and reproducibility of such platforms remain underexplored. In this preliminary study, we synthesized a series of neoglycolipids bearing the Thomsen-Nouveau (Tn) antigen using bio-orthogonal thiol-ene click chemistry. Here we present the results obtained using a set of neoglycolipids that were evaluated for their ability to self-assemble into liposomal vesicles and for in vitro cytotoxicity. The resulting neoglycolipids exhibited no detectable cytotoxicity and formed stable liposomal structures when formulated with palmitic acid and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine via a freeze-thaw/extrusion process. This early-stage work presents a proof of concept for a tunable, liposomal-based synthetic vaccine platform.